Low-dose aspirin and ibuprofen's sterilizing effects on mycobacterium tuberculosis suggest safe newadjuvant therapies for tuberculosis

Journal of Infectious Diseases

Volumn 208, Issue 11, 2013, Pages 1925-1927

  Eisen, Damon P ^a,b   McBryde, Emma S ^a,b   Walduck, Anna ^c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ETANERCEPT; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; LIPOXIN A; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BACTERIAL GROWTH; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; LETTER; LOW DRUG DOSE; MURINE MODEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBERCULOSIS;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; HUMANS; IBUPROFEN; MICE; MICE, INBRED C3H; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84888582526     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit476     Document Type: Letter

References (12)

1. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013; 208:199-202.
2. Ivanyi J, Zumla A. Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J Infect Dis 2013; 208:185-8.
3. Chen M, Divangahi M, Gan H, et al. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 2008; 205:2791-801.
4. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 1995; 92:9475-9.
5. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265:956-9.
6. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase- 2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23:9247-58.
7. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
8. Skerry C, Harper J, Klunk M, Bishai WR, Jain SK. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS One 2012; 7:e39680.
9. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18:257-64.
10. Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005; 41:201-8.
11. Calderon VE, Valbuena G, Goez Y, et al. A humanized mouse model of tuberculosis. PLoS One 2013; 8:e63331.
12. Driver ER, Ryan GJ, Hoff DR, et al. Evaluation of amouse model of necrotic granuloma formation using mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56:3181-95.